Pseudomonas Aeruginosa Treatment Market Size

Global Pseudomonas Aeruginosa Treatment Market Overview

Pseudomonas Aeruginosa Treatment Market Size was valued at USD 4.9 billion in 2022. The pseudomonas aeruginosa treatment market industry is projected to grow from USD 5.2 Billion in 2023 to USD 9.8 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 8.10% during the forecast period (2023 - 2032). The increased usage of antibiotics for the treatment of pseudomonas aeruginosa infection, as well as the developing multidrug resistance bacteria, boosted the demand for antibacterial research and innovation are the key market drivers enhancing the market growth.

Source Secondary Research, Primary Research, MRFR Database and Analyst Review

In June 2024, data from a study conducted at a single medical center revealed that individuals with infections caused by multidrug-resistant (MDR) Pseudomonas aeruginosa were more likely to develop resistance when treated with ceftazidime-avibactam (CZA) compared to those treated with ceftolozane-tazobactam. Although both are recognized as primary treatment options for MDR P aeruginosa infections, the rates of resistance that occur after therapy have not been determined. The main objective was to determine if resistance developed within 90 days of starting therapy, which was defined as a four-fold increase in the minimum inhibitory concentration (MIC) compared to the initial level. 

A total of 93 patients were administered C/T, whereas 20 patients received CZA in the trial. The patient demographics, severity of illness, and treatment features were comparable amongst patients treated with either drug. The rates of 30-day survival, microbiologic failure, and recurrent infections were similar in both groups.

In March 2024, Wockhardt, a multinational pharmaceutical and biotechnology corporation, reported the effective utilization of an experimental antibiotic, Zidebactam/Cefepime, in treating a severe case of drug-resistant skull bone infection and pneumonia in a patient who had undergone a kidney transplant. The case pertained to a 62-year-old male who experienced sino-pulmonary infection and skull base osteomyelitis (a condition with a significant likelihood of sequelae, including neuroinfection) caused by NDM-producing Pseudomonas aeruginosa. NDM-producing Pseudomonas aeruginosa is a highly problematic bacterial strain since it is resistant to the majority of antibiotics currently in use. 

In India, there is an increasing issue of antibiotic resistance, particularly with the prevalence of NDM, which poses a significant worry due to the restricted availability of treatment alternatives. The experimental antibiotic, cefepime/zidebactam, developed by Wockhardt, was given to the patient according to the established protocols, and the patient showed a favorable response within 48 hours. Therapeutic drug monitoring (TDM) was employed to customize the dosing regimen for each individual. The patient's infection was effectively cured after 11 weeks of treatment.

Pseudomonas Aeruginosa Treatment Market Trends

• 
  

  Increased use of antibiotics for the treatment of Pseudomonas Aerginosa infection propels market growth.

  
  

The rising use of antibiotics is driving the market CAGR for Pseudomonas Aeruginosa Treatment. The rising death rate from hospital-acquired infection caused by Pseudomonas Aeruginosa bacterium, particularly in immunocompromised patients. It has been discovered that 32% of healthcare-acquired infections result in urinary infections, gastrointestinal infections, respiratory system infections, bone and joint infections, and other disorders, increasing the demand for Pseudomonas Aeruginosa treatment.

Furthermore, the rising prevalence of nosocomial infections caused by P. aeruginosa, such as pneumonia, urinary tract infections (UTI), cystic fibrosis, and blood stream infections, is expected to boost the worldwide pseudomonas aeruginosa infection treatment market CAGR throughout the forecast period. In addition, increased frequency of bacterial infections, specifically Pseudomonas aeruginosa infections, in intensive care settings with no effective therapy is expected to stimulate demand for newer antibacterial medicines and antibiotics for Pseudomonas aeruginosa infection treatment.

According to the Centres for Disease Control and Prevention (CDC), around 51,000 P. aeruginosa infections in health care settings occur in the United States each year. More over 6,000 (13%) of them are multidrug-resistant, resulting in around 400 deaths every year. According to the "WHO" 2019 estimate, around 51,000 cases of pseudomonas aeruginosa infection are discovered in the United States each year.  According to the "Agency for Healthcare Research and Quality" in 2019, approximately 650,000 people with pseudomonas aeruginosa infections are found each year around the world. In 2017, the American Association for the Advancement of Science found that 7.9% of patients with a hospital-acquired infection in Canadian hospitals..

Pseudomonas Aeruginosa Treatment Market Segment Insights

Pseudomonas Aeruginosa Treatment Medication Insights

The pseudomonas aeruginosa treatment market segmentation, based on type includes monotherapy, combination therapy. The combination therapy segment has the largest market revenue share. The rise in monotherapy medication resistance has increased the demand for combination therapy to treat P. aeruginosa infection. Combination therapy enhances adherence, synergy, and efficacy while lowering side effects and costs. These reasons will drive the combination therapy market forward. Furthermore, the early beginning of action, high bioavailability rate, cost savings, and high efficiency of combination therapy for the treatment of pseudomonas aeruginosa infection are related to the expansion of combination therapy.

Figure1 Pseudomonas Aeruginosa Treatment Market, by Medication, 2022 & 2032 (USD billion)

Source Secondary Research, Primary Research, MRFR Database and Analyst Review

Pseudomonas Aeruginosa Treatment Route of Administrative Insights

The pseudomonas aeruginosa treatment market segmentation, based on route of administrative, includes oral, intravenous, nasal. The oral segment accounted for the largest revenue share of the market in 2022 and is likely to dominate the market over the forecast period due to being the most significant segment in terms of route of administration. The substance or medicines are administered orally. Antibiotics are used in the oral treatment of Pseudomonas Aeruginosa. These elements are largely fueling the segment's growth.

Pseudomonas Aeruginosa Treatment Distribution Channel Insights

Based on distribution channel, the pseudomonas aeruginosa treatment market is divided into hospital pharmacies, retail pharmacies, and online pharmacies. Due to the regular purchase of medicines over time, the retail pharmacies sector accounted for the largest revenue share.  Due to the online platform providing both prescribed and over-the-counter (OTC) pharmaceuticals to the customer's doorstep, online pharmacies have the greatest CAGR during the forecast period. These factors are propelling the market in this category forward.

Pseudomonas Aeruginosa Treatment Regional Insights

By Region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. In 2022, North America has the highest revenue share in the Pseudomonas Aeruginosa Infection Treatment Market and is likely to maintain its dominance during the forecast period. The increasing incidence of antibiotic-resistant diseases, as well as continuing projects, the development of innovative treatments, and the launch of several drugs into the North American market, are primarily responsible for revenue growth in the industry.

Further, the major countries studiedin the market report are The U.S., Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure2 PSEUDOMONAS AERUGINOSA TREATMENT MARKET SHARE BY REGION 2022 (%)

Source Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe’s pseudomonas aeruginosa treatment market accounts for the second-largest market share due to growing number of retail pharmacies and online pharmacies are also contributing to regional growth. Further, the German pseudomonas aeruginosa treatment market held the largest market share, and the UK pseudomonas aeruginosa treatment market was the fastest-growing market in the European region

The Asia-Pacific Pseudomonas Aeruginosa Treatment Market is expected to grow at the fastest CAGR from 2023 to 2032. This is because of the expansion of healthcare facilities and an increase in the number of old persons. Moreover, China’s pseudomonas aeruginosa treatment market held the largest market share, and the Indian pseudomonas aeruginosa treatment market was the fastest growing market in the Asia-Pacific region.

Pseudomonas Aeruginosa Treatment Key Market Players& Competitive Insights

Leading market players are extensively investing in research and development in order to extend their product lines, which will help the pseudomonas aeruginosa therapy market grow even more. Market participants are also engaging in a number of strategic initiatives to grow their worldwide presence, with significant market developments including new product launches, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, the pseudomonas aeruginosa treatment industry must provide cost-effective products.

Manufacturing locally to reduce operational costs is one of the primary business methods utilized by manufacturers in the worldwide pseudomonas aeruginosa treatment industry to benefit clients and expand the market sector. In recent years, the pseudomonas aeruginosa treatment industry has provided some of the most significant advances to medicine. Major players in the pseudomonas aeruginosa therapy market are Merck & Co., Inc. (US), AmpliPhi Biosciences Corp (US), and Bristol-Myers Squibb Co. (US). Allergan PIc (Ireland), Janssen Pharmaceuticals, Inc, and others are aiming to improve market demand by investing in R&D operations.

Merck & Co., Inc. is an American multinational pharmaceutical corporation located in Rahway, New Jersey. It is named after the Merck Group, which was formed in Germany in 1668 and was previously the American part of the Merck Group. Outside of the United States and Canada, the company is known as Merck Sharp & Dohme, or MSD. It is one of the world's major pharmaceutical corporations, consistently ranking in the top five in terms of revenue. Merck & Co. was founded in 1891 as the American subsidiary of Merck Group. Merck develops and manufactures pharmaceuticals, vaccines, biologic therapies, and animal health products. In February 2019, Merck & Co. Inc. announced that Zerbaxa has been approved by the US Food and Drug Administration. This drug is used to treat adult patients with nosocomial pneumonia and ventilator-related pneumonia caused by susceptible gram-negative bacteria.

Allergan plc is a pharmaceutical business based in the United States and Ireland that acquires, develops, manufactures, and markets brand-name pharmaceuticals and medical devices in the fields of medical aesthetics, eye care, central nervous system, and gastroenterology. Botox is manufactured by this company. Allergan plc was founded in March 2015 when Irish-registered Actavis plc acquired Allergan, Inc. and assumed the Allergan moniker. In September 2019, Allergan Inc. gained FDA approval for the "AVYCAZ treatment" in the United States. This medicine is used to treat intra-abdominal infections (cIAI) and urinary tract infections (cUTI) in children.

Key Companies in the pseudomonas aeruginosa treatment market include

• Gilead Sciences Inc. (US)


• Teva Pharmaceutical Industries Ltd (Israel)


• Novartis AG (Switzerland)


• Pfizer inc. (UK)


• Lupin Pharmaceuticals Inc. (US)


• PARI Medical Holding GmbH (Germany)


• AstraZeneca (UK)


• Humanigen Inc (US)


• Merck & Co Inc. (US)


• AmpliPhi Biosciences Corp (US) among Others

Pseudomonas Aeruginosa Treatment Industry Developments

In October 2019, Teva Pharmaceutical debuted new drugs, including "Tobramycin inhalation solution." This drug is used to treat cystic fibrosis individuals who have a Pseudomonas aeruginosa bacterial infection.

In September 2019, Pfizer got FDA approval for the antibiotics avibactam and ceftazidime in the medication "Zavicefta" (ceftazidime-avibactam). It is an antibacterial combination with a set dose that was created to treat serious gram-negative bacterial infections                         

In May 2021, Teva Pharmaceuticals, a subsidiary of Teva Pharmaceutical Industries Ltd. in the United States, has introduced generic Erythromycin tablets in 250 mg and 500 mg strengths. These tablets are a therapeutic equivalent to Arbour Pharmaceuticals' reference listed drug (RLD) Erythromycin Tablets. 

Pseudomonas Aeruginosa Treatment Market Segmentation

Pseudomonas Aeruginosa Treatment Market By Medication Outlook

• Monotherapy


• Combination Therapy

Pseudomonas Aeruginosa Treatment Market By Route Of Administration Outlook

• Oral


• intravenous


• Nasal

Pseudomonas Aeruginosa Treatment Market By Distribution Channel Outlook

• Hospital Pharmacies


• Retail Pharmacies


• Online Pharmacies

Pseudomonas Aeruginosa Treatment Regional Outlook

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe


• Germany
  
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America